Dr. Hannah Kim

65% Complete Response at 50 Months: CAR-T's Triumph in Blood Cancers and Its Unfinished Business in Solid Tumors

I'm Hannah Kim. During my years leading CAR-T R&D at Kite Pharma, I developed a habit: when I look at any clinical data, I check safety first, efficacy second, and commercial potential last. Because t...